FDA批准第一种糖尿病药物 " Victoza " ,在短缺的情况下增加获得治疗的机会。 FDA approves first generic of diabetes drug Victoza, boosting access amid shortages.

林业发展局批准了针对2型糖尿病患者的GLP-1注射Victoza(利拉格卢蒂德)的首个通用版本,这有助于改善获得短缺药物的机会。 The FDA has approved the first generic version of the GLP-1 injection Victoza (liraglutide) for patients with type 2 diabetes, helping to improve access to the drug which has been in short supply. 这种一次性注射辅助手段在与饮食和锻炼同时使用时,用于降低血糖水平。 This once-daily injection aids in lowering blood sugar levels when used alongside diet and exercise. 批准是FDA努力增加复杂药物的获取, 通过加快通用药的审查, 特别是在药物短缺期间的一部分. The approval is part of the FDA's efforts to increase access to complex medications by expediting the review of generics, especially during drug shortages.